Special Issue

Molecular Advances in Lung Cancer: From Pathogenesis to Precision Therapy

Message from the Guest Editor

Submissions are open for a Special Issue of Cancers on "Targeted Therapies for EGFR in Non-Small Cell Lung Cancer". We seek original research, and reviews on EGFR mutations in NSCLC, covering molecular mechanisms, targeted therapy development, resistance mechanisms, and clinical trial evidence. Contributions from lung cancer researchers and clinicians are encouraged. Rigorous peer review will ensure scientific quality. Let's advance our understanding of EGFR-targeted therapies in NSCLC and develop more effective treatments. Looking forward to your valuable submissions.

Guest Editor

Dr. Federico Pio Fabrizio

Faculty of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy

Deadline for manuscript submissions

closed (31 October 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/196555

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

